Results Of 14 671 patients, 7332 were randomized to sitagliptin and 7339 to placebo. Hospitalization for HF occurred in % (n = 228) and % (n = 229) of the sitagliptin and placebo groups, respectively (unadjusted hazard ratio, ; 95% CI, -). There was also no difference in total hHF events between the sitagliptin (n = 345) and placebo (n = 347) groups (unadjusted hazard ratio, ; 95% CI, -). Post-hHF all-cause death was similar in the sitagliptin and placebo groups (% vs %, respectively), as was CV death (% vs %, respectively). No heterogeneity for the effect of sitagliptin on hHF was observed in subgroup analyses across 21 factors ( P > .10 for all interactions). Meta-analysis of the hHF results from the 3 reported DPP4i CV outcomes trials revealed moderate heterogeneity ( I 2 = , P = .16).